Aclaris Therapeutics Director Milano Receives Equity Awards and Vested Shares

This Form 4 filing discloses equity transactions for Vincent Milano, a director of Aclaris Therapeutics, Inc. (ACRS). On June 4, 2026, Milano received a stock option grant for 42,350 shares with an exercise price of $4.71, which vests monthly starting July 4, 2026, and expires June 3, 2036. He also received 10,987 restricted stock units that vest on June 4, 2027. On June 5, 2026, 11,580 restricted stock units vested and converted to common stock, which Milano acquired. Following these transactions, Milano holds 28,896 shares of common stock directly, plus the unvested equity awards. These grants were made under the company's non-employee director compensation policy and 2025 Equity Incentive Plan.